ALX Oncology Holdings Inc.
ALXO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $17,441 | $18,022 | $23,888 | $23,532 |
| G&A Expenses | $5,091 | $5,451 | $7,932 | $7,081 |
| SG&A Expenses | $5,091 | $5,451 | $7,932 | $7,081 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3,175 | $0 | $0 |
| Operating Expenses | $22,532 | $26,648 | $31,820 | $30,613 |
| Operating Income | -$22,532 | -$26,648 | -$31,820 | -$30,613 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $388 | $699 | $1,066 | $1,450 |
| Pre-Tax Income | -$22,144 | -$25,949 | -$30,754 | -$29,163 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22,144 | -$25,949 | -$30,754 | -$29,163 |
| % Margin | – | – | – | – |
| EPS | -0.41 | -0.49 | -0.58 | -0.55 |
| % Growth | 16.3% | 15.5% | -5.5% | – |
| EPS Diluted | -0.41 | -0.49 | -0.58 | -0.55 |
| Weighted Avg Shares Out | 53,577 | 53,446 | 53,359 | 52,802 |
| Weighted Avg Shares Out Dil | 53,577 | 53,446 | 53,359 | 52,802 |
| Supplemental Information | – | – | – | – |
| Interest Income | $802 | $1,106 | $1,483 | $1,878 |
| Interest Expense | $408 | $405 | $406 | $427 |
| Depreciation & Amortization | $153 | $191 | $211 | $214 |
| EBITDA | -$21,583 | -$25,353 | -$30,137 | -$28,522 |
| % Margin | – | – | – | – |